Circadian rhythm biomarker from wearable device data is related to concurrent antidepressant treatment response.

Major depressive disorder (MDD) is associated with circadian rhythm disruption. Yet, no circadian rhythm biomarkers have been clinically validated for assessing antidepressant response. In this study, 40 participants with MDD provided actigraphy data using wearable devices for one week after initiating antidepressant treatment in a randomized, double-blind, placebo-controlled trial.

Gradient boosting decision-tree-based algorithm with neuroimaging for personalized treatment in depression.

Introduction: Pretreatment positron emission tomography (PET) with 2-deoxy-2-[F]fluoro-D-glucose (FDG) and magnetic resonance spectroscopy (MRS) may identify biomarkers for predicting remission (absence of depression). Yet, no such image-based biomarkers have achieved clinical validity. The purpose of this study was to identify biomarkers of remission using machine learning (ML) with pretreatment FDG-PET/MRS neuroimaging, to reduce patient suffering and economic burden from ineffective trials.

Pilomatrixoma breast mimicking carcinoma.

A 50-year-old male with a painless progressively increasing lump of right breast, misdiagnosed on fine needle aspiration cytology as carcinoma breast, operated for modified radical mastectomy, is presented here. Histopathology of the resected specimen revealed pilomatrixoma.